Literature DB >> 12663625

Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.

Giuseppe Lepore, Alessandro R Dodesini, Italo Nosari, Roberto Trevisan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12663625     DOI： 10.2337/diacare.26.4.1321

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  8 in total

1.  Changes in HbA1c and Weight Following Transition to Continuous Subcutaneous Insulin Infusion Therapy in Adults With Type 1 Diabetes.

Authors:  Sanjeev N Mehta; Henrik Ullits Andersen; Martin J Abrahamson; Howard A Wolpert; Eva E Hommel; William McMullen; Martin Ridderstråle
Journal:  J Diabetes Sci Technol       Date:  2016-07-11

Review 2.  The evidence base for diabetes technology: appropriate and inappropriate meta-analysis.

Authors:  John C Pickup
Journal:  J Diabetes Sci Technol       Date:  2013-11-01

Review 3.  Clinical experience with insulin glargine in type 1 diabetes.

Authors:  Satish Garg; Emily Moser; Marie-Paule Dain; Anastasia Rodionova
Journal:  Diabetes Technol Ther       Date:  2010-10-22       Impact factor: 6.118

4.  Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.

Authors:  Eda Cengiz; William V Tamborlane; Melody Martin-Fredericksen; James Dziura; Stuart A Weinzimer
Journal:  Diabetes Care       Date:  2010-02-11       Impact factor: 19.112

Review 5.  Insulin glargine: an updated review of its use in the management of diabetes mellitus.

Authors:  Christopher J Dunn; Greg L Plosker; Gillian M Keating; Kate McKeage; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Basal insulin supplementation in Type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin.

Authors:  R Schiaffini; P I Patera; C Bizzarri; P Ciampalini; M Cappa
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

Review 7.  A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus.

Authors:  Riccardo Candido; Kathleen Wyne; Ester Romoli
Journal:  Diabetes Ther       Date:  2018-04-13       Impact factor: 2.945

8.  Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.

Authors:  Geremia B Bolli; David Kerr; Reena Thomas; Elisabetta Torlone; Agnès Sola-Gazagnes; Ester Vitacolonna; Jean Louis Selam; Philip D Home
Journal:  Diabetes Care       Date:  2009-04-23       Impact factor: 17.152
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.